Assessment of effect of irbesartan and nebivolol on the left atrium volume and deformation in the patients with mild-moderate hypertension.
BACKGROUND
We aimed to assess the effects of irbesartan and nebivolol on the left atrium (LA) volume and deformation in the patients with mild-moderate hypertension.


METHODS
The study comprised of 160 patients (mean age: 55.6±9.6 years), who had Stage 1 or 2 hypertension according to the European Society of Cardiology (ESC) and have not been receiving antihypertensive therapy. The patients were assigned to treatment groups; irbesartan (n=80) and nebivolol (n=80). The patients were clinically and echocardiographically reevaluated on the 6th and 12th months after the onset of treatment.


RESULTS
There was no difference between the two treatment groups in terms of baseline demographic, clinical and echocardiographic characteristics. Moreover, no difference was observed between the treatment groups on the 6th and 12th months. Intragroup analyses revealed that systolic blood pressure (SBP) and diastolic blood pressure (DBP) significantly decreased in time and diastolic function parameters were improved. However, whilst significant increase was observed in conduit volume, decrease was observed in other volumes of the LA in the irbesartan and nebivolol groups. This significant change was observed on the 6th month in both treatment groups. LA global peak systolic strain (LAGLSs), LA global peak systolic strain rate (LAGLSRs), LA global peak strain rate during early ventricular diastole (LAGLSRe) and LA global peak strain rate (LAGLSRa) during late ventricular diastole (LAGLSRa) values began to be significantly increased after 6 months of treatment in both treatment groups.


CONCLUSIONS
We found that nebivolol, which is a new generation beta blocker, is effective as irbesartan with proven efficacy in improving LA volume and LA myocardial performance in patients with mild-moderate hypertension. Moreover, we determined that strain and strain rate, which are the new echocardiographic parameters, are effective as LA volumes in assessing LA functions.
Department of Cardiology, Erzincan University, Erzincan, Turkey. demirelli23@yahoo.com.
H
H
Degirmenci
H
H
Duman
S
S
Demirelli
E M
EM
Bakirci
H
H
Hamur
S
S
Inci
Z
Z
Simsek
L
L
Askın
A
A
Arısoy
Z
Z
Lazoglu
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001578:Benzopyrans / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D003971:Diastole / Q000187:drug effects; D004452:Echocardiography / Q000379:methods; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006325:Heart Atria / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D000077405:Irbesartan; D008297:Male; D008875:Middle Aged; D000068577:Nebivolol; D011446:Prospective Studies; D013599:Systole / Q000187:drug effects; D013777:Tetrazoles / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D001578:Benzopyrans; D001713:Biphenyl Compounds; D004983:Ethanolamines; D013777:Tetrazoles; D000068577:Nebivolol; D000077405:Irbesartan